[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-complication":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100480028","early-phase-1-a-study-to-determine-the-preferred-dose-of-the-drug-lisinopril-for-preventing-urinary-toxicity-following-radiotherapy-for-prostate-cancer-100480028",false,"NCT05530655","A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer","A Phase I Study to Determine the Preferred Dose of the Angiotensin Converting Enzyme Inhibitor Lisinopril for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer","Inclusion Criteria:\n\n* Have a confirmed diagnosis of adenocarcinoma of the prostate and are candidates for curative-intent external beam radiation (with or without androgen deprivation therapy, ADT) at the Wilmot Cancer Institute Department of Radiation Oncology. Radiotherapy may be either primary, adjuvant or salvage. It may be part of combined treatment with androgen deprivation therapy.\n* Be stage M0 based on the standard of care staging imaging\n* Be able to read English\n* Have the psychological ability and general health that permits completion of the study requirements and required follow up\n* Be ≥18 and \\\u003C 70 years of age\n* Have ECOG performance status of 0 to 2 within 180 days prior to enrollment\n* Have adequate renal function with creatinine clearance \\> 30 mL\u002Fmin within 30 days prior to registration\n* Have hematologic and hepatic function deemed adequate for planned treatment by the treating investigator within 90 days prior to registration, including:\n* hemoglobin ≥9.0 g\u002FdL, independent of transfusion and\u002For growth factors\n* platelet count ≥100,000\u002FµL independent of transfusion and\u002For growth factors\n* Have a baseline systolic blood pressure of \\>130.\n\nExclusion Criteria:\n\n* Have received prior pelvic radiotherapy\n* Be taking lisinopril or other RAS modifying drug within two months prior to registration\n* Have had a prior allergic reaction to lisinopril","MALE","18 Years","70 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.",[27,28,29],"Prostate Cancer","Radiation Toxicity","Urinary Complication","RECRUITING","2026-01-09",{"date":33,"type":34},"2026-01-13","ACTUAL",{"date":36,"type":34},"2024-02-20",{"date":38,"type":21},"2028-01-01",{"name":40,"class":41},"University of Rochester","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100572755","postoperative-bladder-filling-after-outpatient-laparoscopic-hysterectomy-and-time-to-discharge-100572755","NCT06737393","Postoperative Bladder Filling After Outpatient Laparoscopic Hysterectomy and Time to Discharge","Postoperative Bladder Filling After Outpatient Laparoscopic Hysterectomy and Time to Discharge: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 18 to 80\n* Undergoing planned laparoscopic hysterectomy as a day surgery procedure\n\nExclusion Criteria:\n\n* Women younger than 18 or older than 80 years of age\n* Undergoing a non-laparoscopic unplanned surgical procedure",true,"FEMALE","80 Years",{"count":54,"type":21},112,[56],"NA","The investigators hypothesize that backfilling the bladder postoperatively will reduce time to spontaneous void and subsequent discharge from the post-anesthesia care unit.",[59,29],"Patient Discharge","2024-12-15",{"date":62,"type":34},"2024-12-17",{"date":64,"type":21},"2025-01-01",{"date":66,"type":21},"2026-01-01",{"name":68,"class":41},"University of Tennessee"]